|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:affects
|
central nervous system
|
|
gptkbp:canBe
|
prescription drugs
illicit drugs
|
|
gptkbp:cause
|
addiction
dependence
changes in behavior
changes in cognition
changes in consciousness
changes in mood
changes in perception
|
|
gptkbp:example
|
gptkb:paroxetine
gptkb:ketamine
gptkb:morphine
gptkb:valproic_acid
gptkb:phencyclidine
gptkb:benzodiazepines
gptkb:sertraline
gptkb:bupropion
gptkb:MDMA
gptkb:carbamazepine
gptkb:clozapine
gptkb:fluoxetine
gptkb:haloperidol
gptkb:olanzapine
gptkb:diazepam
gptkb:methylphenidate
gptkb:trazodone
cannabis
psilocybin
cocaine
LSD
amphetamine
barbiturates
mescaline
lithium carbonate
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
psychotropic substances
|
|
gptkbp:includes
|
antipsychotics
mood stabilizers
antidepressants
anxiolytics
hallucinogens
stimulants
sedatives
hypnotics
|
|
gptkbp:mayInclude
|
controlled substances
side effects
|
|
gptkbp:regulates
|
gptkb:United_Nations_Convention_on_Psychotropic_Substances
|
|
gptkbp:used_in
|
mental health treatment
|
|
gptkbp:bfsParent
|
gptkb:Convention_on_Psychotropic_Substances
gptkb:United_Nations_Convention_Against_Illicit_Traffic_in_Narcotic_Drugs_and_Psychotropic_Substances
gptkb:United_Nations_Convention_against_Illicit_Traffic_in_Narcotic_Drugs_and_Psychotropic_Substances
gptkb:Schedule_VI
gptkb:National_Campaign_Against_Drug_Abuse_Authority_(NACADA)
gptkb:Narcotic_Drugs_and_Psychotropic_Substances_Act,_1985
gptkb:Schedule_I_(Convention_on_Psychotropic_Substances)
|
|
gptkbp:bfsLayer
|
7
|